Clinical Trials Browser

temsirolimus × Plasma cell × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed

180 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

63 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT00079456 2013-10-11

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

25 enrolled

Plasma cell

Multiple Myeloma

NCT00398515 2013-09-30

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Phase 1 Completed

25 enrolled

Plasma cell

Multiple Myeloma

Clinical Trials

CAPTUR

TAPUR

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma